Compare ResMed Inc. (RMD) vs Direxion Daily S&P 500 Bull 3X Shares (SPXL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ResMed Inc. vs Direxion Daily S&P 500 Bull 3X Shares — how do they compare? ResMed Inc. trades at $230.05 (market cap $31.89B), while Direxion Daily S&P 500 Bull 3X Shares trades at $297.97 (market cap $7.36B). The key difference: ResMed Inc. is far larger — about 4.3× Direxion Daily S&P 500 Bull 3X Shares's market cap, and ResMed Inc. pays a 1.16% dividend while Direxion Daily S&P 500 Bull 3X Shares pays none. Which is the better fit depends on your goals — on Pluang, investors hold ResMed Inc. for 51 Days and Direxion Daily S&P 500 Bull 3X Shares for 32 Days on average.
| RMD | SPXL | |
|---|---|---|
Market Cap | $31.89B | $7.36B |
Volume | 618,314 | 1,835,467 |
Sector | Health | Leveraged / Inverse |
52-Week High | $275.96 | $301.38 |
52-Week Low | $182.82 | $170.20 |
Typical Hold Time | 51 Days | 32 Days |
Enterprise Value | $31.24B | — |
Dividend Yield | 1.16% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ResMed (RMD) trades at $226.73, up 0.33% on the day, with a bullish technical signal supported by moving averages. The company reported strong earnings beats in recent quarters, with Q3 2026 results pending. Revenue grew to $5.15 billion in 2025, with a net income margin of 26.94%, while cash flow from operations reached $1.75 billion. Recent news highlights an upcoming earnings report and positive analyst commentary on growth prospects.
The outlook is positive, driven by consistent earnings outperformance and a consensus price target of $242.70, implying upside. Key risks include competitive pressures and ongoing legal investigations. Institutional interest remains strong, with recent stake increases by funds. The stock's valuation metrics, such as a P/E of 21.74, appear reasonable given growth expectations.
SPXL, a leveraged ETF tracking the S&P 500, trades at $293.05, down 1.28% on the day. Technical indicators show a bullish trend with strong moving average support, though oscillators remain neutral. The ETF reflects broader market sentiment where S&P 500 earnings are expected to grow 35% in 2026 (24/7 Wall Street, 2026-10-03), yet concerns about profit growth slowing to 15% in 2027 and high concentration in top holdings create uncertainty.
The outlook for SPXL is tied to S&P 500 performance, with Wall Street projecting a 21% rise to 9,275 by September 2027 (The Motley Fool, 2026-09-30). Key risks include market volatility, geopolitical tensions, and slowing earnings growth. Opportunities lie in seasonal bullish trends and AI-driven corporate spending, but leveraged exposure amplifies both gains and losses.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About ResMed Inc.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →About Direxion Daily S&P 500 Bull 3X Shares
SPXL aims for 300% of the S&P 500's daily performance. It uses swaps and futures to provide 3x leverage, making it a high-risk tool for short-term traders. Due to daily resets, it is prone to volatility decay and is not intended for long-term holding.
Read more on SPXL →
